Is the interaction between felbamate and valproate against seizures induced by 4-aminopyridine and pentylenetetrazole in mice beneficial?

Pharmacological Research

Volumn 48, Issue 2, 2003, Pages 183-192

  Cuadrado, Antonio ^a   Amat, Gaspar ^a   Armijo, Juan A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

4 Aminopyridine; Drug interaction; Felbamate; Pentylenetetrazole; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOPYRIDINE; ANTICONVULSIVE AGENT; FELBAMATE; PENTETRAZOLE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG POTENCY; MALE; MODEL; MONOTHERAPY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

EID: 0038205825     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00084-7     Document Type: Article

References (43)

1. Leach J.P. Polypharmacy with anticonvulsants: focus on synergism. CNS Drugs. 8:1997;366-375.
2. Czuczwar S.J., Przesmycki K. Felbamate, gabapentin and topiramate as adjuvant antiepileptic drugs in experimental models of epilepsy. Pol. J. Pharmacol. 53:2001;65-68.
3. Bourgeois B.F.D. Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J. Pharmacol. Exp. Ther. 247:1988;1128-1132.
4. Rowan A.J., Meijer J.W.A., de Beer-Pawlikowski N., van der Geest P., Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch. Neurol. 40:1983;797-802.
5. De Sarro G., Nava F., Aguglia U., De Sarro A. Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Neuropharmacology. 35:1996;153-158.
6. Panayiotopoulos G.P., Ferrie C.D., Knott C., Robinson R.O. Interaction of lamotrigine with sodium valproate. Lancet. 341:1993;445. (letter).
7. Pisani F., Di Perri R., Perucca E., Richens A. Interaction of lamotrigine with sodium valproate. Lancet. 341:1993;1224. (letter).
8. Ferrie C.D., Robinson R.O., Knott C., Panayiotopoulos C.P. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol. Scand. 91:1995;200-202.
9. Ferrie C.D., Panayiotopoulus C.P. Therapeutic interactions of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure. 3:1994;157-159.
10. Brodie M.J., Yuen A.W.C. 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. 26:1997;423-432.
11. McCabe P.H., Michel N.C., McNew C.D. Clinical efficacy of combination therapy with valproic acid and lamotrigine in intractable epilepsy: high success rate with low incidence of rash. Epilepsia. 39:1998;49. (abstract).
12. Privitera M., Welty T.E. Lamotrigine combined with valproate for idiopathic generalized epilepsy. Epilepsia. 39:1998;52. (abstract).
13. Pisani F., Oteri G., Russo M.F., Di Perri R., Perucca E., Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 40:1999;1141-1146.
14. McCabe P.H., McNew C.D., Michel N.C. Effect of divalproex-lamotrigine combination therapy in frontal lobe seizures. Arch Neurol. 58:2001;1264-1268.
15. Arzimanoglou A., Kulak I., Bidaut-Mazel C., Baldy-Moulinier M. Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy. Rev. Neurol. 157:2001;525-536.
16. Pennell P., Ogaily M., Macdonald R. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology. 45:1995;456-460.
17. Kaufman D., Kelly J., Anderson T.et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia. 38:1997;1265-1269.
18. O'Neil M., Perdun C., Wilson M.et al. Felbamate-associated fatal hepatic necrosis. Neurology. 46:1996;1457-1459.
19. Pellock J.M. Felbamate. Epilepsia. 40(Suppl 5):1999;S57-S62.
20. French J., Smith M., Faught E., Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Neurology. 52:1999;1540-1545.
21. Schmidt D., Bourgeois B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Safety. 22:2000;467-477.
22. Fraser C.M., Sills G.J., Forrest G., Thompson G.G., Brodie M.J. Neurochemical studies with the anticonvulsant felbamate in mouse brain. Pharmacol. Res. 40:1999;257-261. (doi:10.1006/phrs.1999.0511).
23. Cilio M.R., Kartashov A.I., Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res. 47:2001;1-7.
24. White H.S. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 40(Suppl 5):1999;S2-S10.
25. Siegel H., Kelley K., Stertz B., Reeves-Tyer P., Flamini R., Malow B.et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res. 34:1999;91-97.
26. Gordon R., Gels M., Wichmann J.K., Diamantis W., Sofia R.D. Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice. Epilepsia. 34:1993;367-371.
27. Yamaguchi S., Rogawski M.A. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res. 11:1992;9-16.
28. Cramer C.L., Stagnitto M.L., Knowles M.A., Palmer G.C. Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of antiepileptic agents and calcium antagonists. Life Sci. 54:1994;271-275.
29. White HS, Wolf HH, Woodhead JH, Kupferberg HJ. The National Institute of Health anticonvulsant drug development program: screening for efficacy. In: French J, Leppik I, Dichter MA, editors. Antiepileptic drug development. Advances in neurology, vol. 76. Philadelphia: Lippincott-Raven; 1998. p. 29-39.
30. Löscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. 3. Pentylenetetrazole seizure models. Epilepsy Res. 8:1991;171-189.
31. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 46:1957;208-209.
32. Fraser A.D., MacNeil W., Isner A.F., Camfield P.R. Lamotrigine analysis in serum by high-performance liquid chromatography. Ther. Drug Monit. 17:1995;174-178.
33. Turnell D.C., Cooper J.D.H. Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. Clin. Chem. 28:1982;527-531.
34. Valdizán E.M., Armijo J.A. Effects of single and multiple increasing doses of vigabatrin on brain GABA metabolism and correlation with vigabatrin plasma concentration. Biochem. Pharmacol. 43:1992;2143-2150.
35. Löscher W., Fassbender C.P., Gram L., Gramer M., Hörstermann D., Zahner B.et al. Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: correlation between clinical response to vigabatrin and increase in plasma GABA. Epilepsy Res. 14:1993;245-255.
36. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
37. Levy RH, Bourgeois BFD. Drug-drug interactions. In: Engel Jr J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 1175-9.
38. Leach J.P., Sills G.J., Butler E., Forrest G., Thompson G.G., Brodie M.J. Neurochemical actions of gabapentin in mouse brain. Epilepsy Res. 27:1997;175-180.
39. Chez M.G., Bourgeois B.F.D., Pippenger C.E., Knowles W.D. Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice. Clin. Neuropharmacol. 17:1994;32-37.
40. Sofia RD. Felbamate: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press; 1995. p. 791-7.
41. Armand V., Rundfelst C., Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol. 359:1999;33-39.
42. Bourgeois B.F.D. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin. Neuropharmacol. 11:1988;348-359.
43. Sayin Ü., Cengiz S., Altug T. Vigabatrin as an anticonvulsant against pentylentetrazole seizures. Pharmacol. Res. 28:1993;325-331.